Galderma Continues Global Growth Ambition With Sculptra (injectable poly-L-lactic Acid) Re-launch in Europe
Updated protocol allows for faster and more convenient administration of
Sculptra
with the optional addition of lidocaine to increase patient comfort
Update is based on new data from physiochemical and clinical studies evaluating the safety and effectiveness of
Sculptra
Virtual event held with European healthcare professionals to mark re-launch provided additional education and support on new protocol
Galderma today announced a European re-launch of
Sculptra (injectable poly-L-lactic acid) a collagen stimulator with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients.
Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe
Thursday, March 4, 2021 1:52PM IST (8:22AM GMT)
Updated protocol allows for faster and more convenient administration of
Sculptra® with the optional addition of lidocaine to increase patient comfort
Update is based on new data from physiochemical and clinical studies evaluating the safety and effectiveness of
Sculptra®
Virtual event held with European healthcare professionals to mark re-launch provided additional education and support on new protocol
Galderma today announced a European re-launch of
Sculptra
® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients.
Galderma Receives FDA Approval for Restylane® Defyne for Chin Augmentation
Represents second approved indication for Restylane Defyne in U.S.; expands Galderma Aesthetics growing Restylane product portfolio
News provided by
Share this article
Share this article
FORT WORTH, Texas, Feb. 2, 2021 /PRNewswire/ Galderma announces that the U.S. Food and Drug Administration (FDA) has approved
Restylane
® Defyne for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21.
1 In 2020 alone, online searches for chin enhancement increased by 185 percent, reinforcing the emerging patient need for a product like
Restylane Defyne.
2
Restylane Defyne is the first and only chin filler to demonstrate results across a wide range of participants
Share this article
Share this article
HOUSTON, Jan. 26, 2021 /PRNewswire/ Soliton, Inc., (Nasdaq: SOLY) ( Soliton or the Company ), a medical device company with a novel and proprietary platform technology, today announced it has entered into a collaboration with the US Navy to conduct a multi-treatment proof-of-concept clinical study to evaluate the safety, and efficacy of multiple treatments with Soliton s Rapid Acoustic Pulse (RAP) device for the improvement in the appearance of fibrotic scars. The study will be a US-based, single-center, prospective trial, examining a maximum of 25 patients. We are extremely pleased to collaborate with the US Navy and investigate the safety and efficacy of our RAP device in improving the appearance of fibrotic scars, commented Brad Hauser, Soliton CEO and President. The results from our previous proof-of-concept Keloid and Hypertrophic Scar trial were extremely encouraging, as the RAP device demonstrated reductions in both the volume o